PMID- 33621403
OWN - NLM
STAT- MEDLINE
DCOM- 20220310
LR  - 20220311
IS  - 1549-4918 (Electronic)
IS  - 1066-5099 (Linking)
VI  - 39
IP  - 7
DP  - 2021 Jul
TI  - Mesenchymal stromal cell-mediated immune regulation: A promising remedy in the 
      therapy of type 2 diabetes mellitus.
PG  - 838-852
LID - 10.1002/stem.3357 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a major threat to global public health, with 
      increasing prevalence as well as high morbidity and mortality, to which immune 
      dysfunction has been recognized as a crucial contributor. Mesenchymal stromal 
      cells (MSCs), obtained from various sources and possessing potent 
      immunomodulatory abilities, have displayed great therapeutic potential for T2DM. 
      Interestingly, the immunomodulatory capabilities of MSCs are endowed and plastic. 
      Among the multiple mechanisms involved in MSC-mediated immune regulation, the 
      paracrine effects of MSCs have attracted much attention. Of note, extracellular 
      vesicles (EVs), an important component of MSC secretome, have emerged as pivotal 
      mediators of their immunoregulatory effects. Particularly, the necrobiology of 
      MSCs, especially apoptosis, has recently been revealed to affect their 
      immunomodulatory functions in vivo. In specific, a variety of preclinical studies 
      have demonstrated the beneficial effects of MSCs on improving islet function and 
      ameliorating insulin resistance. More importantly, clinical trials have further 
      uncovered the therapeutic potential of MSCs for T2DM. In this review, we outline 
      current knowledge regarding the plasticity and underlying mechanisms of 
      MSC-mediated immune modulation, focusing on the paracrine effects. We also 
      summarize the applications of MSC-based therapies for T2DM in both preclinical 
      studies and clinical trials, with particular emphasis on the modulation of immune 
      system.
CI  - (c) 2021 AlphaMed Press.
FAU - Chen, Ji
AU  - Chen J
AD  - State Key Laboratory of Military Stomatology and National Clinical Research 
      Center for Oral Diseases and Shaanxi International Joint Research Center for Oral 
      Diseases，Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, People's Republic of China.
AD  - Department of Oral Implantology, School of Stomatology, Fourth Military Medical 
      University, Xi'an, People's Republic of China.
FAU - Zheng, Chen-Xi
AU  - Zheng CX
AD  - State Key Laboratory of Military Stomatology and National Clinical Research 
      Center for Oral Diseases and Shaanxi International Joint Research Center for Oral 
      Diseases，Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, People's Republic of China.
FAU - Jin, Yan
AU  - Jin Y
AUID- ORCID: 0000-0002-2586-1152
AD  - State Key Laboratory of Military Stomatology and National Clinical Research 
      Center for Oral Diseases and Shaanxi International Joint Research Center for Oral 
      Diseases，Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, People's Republic of China.
FAU - Hu, Cheng-Hu
AU  - Hu CH
AUID- ORCID: 0000-0003-2443-6485
AD  - State Key Laboratory of Military Stomatology and National Clinical Research 
      Center for Oral Diseases and Shaanxi International Joint Research Center for Oral 
      Diseases，Center for Tissue Engineering, School of Stomatology, The Fourth 
      Military Medical University, Xi'an, People's Republic of China.
AD  - Xi'an Institute of Tissue Engineering and Regenerative Medicine, Xi'an, People's 
      Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210302
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
SB  - IM
MH  - Apoptosis
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - *Extracellular Vesicles
MH  - Humans
MH  - Immunomodulation
MH  - *Mesenchymal Stem Cells
OTO - NOTNLM
OT  - cellular therapy
OT  - diabetes
OT  - immunotherapy
OT  - mesenchymal stromal cells
OT  - secretome
EDAT- 2021/02/24 06:00
MHDA- 2022/03/11 06:00
CRDT- 2021/02/23 17:35
PHST- 2020/08/19 00:00 [received]
PHST- 2021/02/03 00:00 [accepted]
PHST- 2021/02/24 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/02/23 17:35 [entrez]
AID - 10.1002/stem.3357 [doi]
PST - ppublish
SO  - Stem Cells. 2021 Jul;39(7):838-852. doi: 10.1002/stem.3357. Epub 2021 Mar 2.